Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prone versus supine radiotherapy for right-sided breast cancer - a retrospective study of radiotherapy plans.

Radiation oncology (London, England)·2026
Same author

Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer.

The Lancet. Oncology·2026
Same author

Endoscopic Lung Volume Reduction with Valves Improves Cardiovascular Adaptability and 6-MWT Performance in Severely Limited COPD Patients.

International journal of chronic obstructive pulmonary disease·2026
Same author

Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer.

CA: a cancer journal for clinicians·2026
Same author

Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. <i>Cancers</i> 2026, <i>18</i>, 124.

Cancers·2026
Same author

IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma.

Blood·2026

Related Experiment Video

Updated: Jul 3, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.7K

Salvage Radiotherapy for Relapsed Prostate Cancer after Radical Prostatectomy Is Associated with Normal Life

Gunnar Lohm1,2, Franz Knörnschild3, Konrad Neumann4

  • 1Department of Radiation Oncology, Johanniter-Hospital Genthin-Stendal, 39576 Stendal, Germany.

Cancers
|February 10, 2024
PubMed
Summary

Salvage radiotherapy (SRT) after prostatectomy for prostate cancer (PCa) progression shows similar overall survival (OS) compared to controls. SRT prolongs prostate-specific antigen doubling time, indicating a survival benefit for PCa patients.

Keywords:
PSA doubling timebiochemical relapseoverall survivalprostate cancersalvage radiotherapy

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

Related Experiment Videos

Last Updated: Jul 3, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.7K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Urology

Background:

  • Salvage radiotherapy (SRT) improves survival in prostate cancer (PCa) patients with biochemical progression (BP) after radical prostatectomy (RP).
  • No prospective randomized trials have directly compared SRT to no treatment in this setting.
  • Understanding risk factors and survival outcomes is crucial for guiding treatment decisions.

Purpose of the Study:

  • To compare the overall survival (OS) of patients receiving SRT for post-RP BP with age-matched controls.
  • To identify risk factors associated with biochemical progression (BP) and OS after SRT.
  • To evaluate changes in prostate-specific antigen doubling time (PSADT) before and after SRT.

Main Methods:

  • Analysis of 151 patients who received SRT for post-RP BP.
  • Comparison of OS with 151,000 virtual, age-matched controls from government life tables.
  • Investigation of risk factors for BP and OS; comparison of pre- and post-SRT PSADT.

Main Results:

  • Gleason score, pre-SRT PSA, and negative surgical margins were significant risk factors for BP, but not OS.
  • Median PSADT significantly prolonged after SRT (3.7 vs. 8.3 months, p < 0.001).
  • No significant difference in OS between SRT patients and virtual controls (p = 0.112), suggesting a survival benefit from SRT.

Conclusions:

  • SRT for post-prostatectomy biochemical progression in prostate cancer patients is associated with similar overall survival compared to general population controls.
  • The significant prolongation of PSADT post-SRT supports its beneficial role in managing PCa.
  • Limitations include lack of systematic recording of subsequent treatments, which may influence outcomes.